Kathmere Capital Management LLC Sells 460 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Kathmere Capital Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,504 shares of the biopharmaceutical company’s stock after selling 460 shares during the period. Kathmere Capital Management LLC’s holdings in Gilead Sciences were worth $172,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Abich Financial Wealth Management LLC increased its stake in shares of Gilead Sciences by 88.4% during the first quarter. Abich Financial Wealth Management LLC now owns 2,219 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 1,041 shares during the period. Keynote Financial Services LLC bought a new position in Gilead Sciences during the 1st quarter worth $845,000. IMS Capital Management boosted its position in shares of Gilead Sciences by 34.8% in the first quarter. IMS Capital Management now owns 6,623 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,710 shares during the period. Railway Pension Investments Ltd grew its stake in shares of Gilead Sciences by 0.3% in the first quarter. Railway Pension Investments Ltd now owns 1,563,965 shares of the biopharmaceutical company’s stock valued at $114,560,000 after acquiring an additional 4,800 shares in the last quarter. Finally, Cetera Advisors LLC increased its position in Gilead Sciences by 167.2% during the first quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock worth $6,064,000 after acquiring an additional 51,801 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.4 %

NASDAQ GILD traded up $0.28 during trading hours on Friday, reaching $76.77. The company’s stock had a trading volume of 6,458,108 shares, compared to its average volume of 6,392,589. The firm has a fifty day simple moving average of $68.80 and a 200-day simple moving average of $70.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a market cap of $95.64 billion, a P/E ratio of 213.25, a P/E/G ratio of 3.37 and a beta of 0.18.

Analyst Ratings Changes

A number of research analysts have issued reports on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. TD Cowen reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research note on Monday, July 8th. Finally, Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $81.81.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.